Subject Index - Osteoporosis

A
Actonel. See Risedronate
Alcohol intake
Alendronate
	vertebral fracture
	nonvertebral fracture
	long-term alendronate
	preexisting vertebral fracture
	upper GI tract complaints
	vertebral osteoporosis
	intermittent alendronate
	postmenopausal osteoporosis
	cost savings
	women with osteoporosis
	addition to ongoing hormone replacement therapy
	alendronate and estrogen
	cyclical etidronate
	etidronate and alendronate
	loss of BMD
	glucocorticoid therapy
	men with osteoporosis
	osteopenia/osteoporosis in children
	Alendronate and parathyroid hormone
	Alendronate compared to etidronate
Alendronate Once-Weekly Study Group
Alendronate Osteoporosis Prevention Study Group
Alendronate/Estrogen Study
Alfacalcidol
	prevention of corticosteroid-induced bone loss
	heart transplant cases
Anticoagulant treatment, effect on fracture risk Top
B
Bisphosphonates
	Alendronate
		vertebral fracture
		nonvertebral fracture
		long-term alendronate
		preexisting vertebral fracture
		upper GI tract complaints
		vertebral osteoporosis
		intermittent alendronate
		postmenopausal osteoporosis
		cost savings
		women with osteoporosis
		addition to ongoing hormone replacement therapy
		alendronate and estrogen
		cyclical etidronate
		etidronate and alendronate
		loss of BMD
		glucocorticoid therapy
		men with osteoporosis
		osteopenia/osteoporosis in children
		Alendronate and parathyroid hormone
		Alendronate compared to etidronate
Alendronate Once-Weekly Study Group
Alendronate Osteoporosis Prevention Study Group
Alendronate/Estrogen Study
Etidronate
Pamidronate
Risedronate
		bisphonate therapy - cost effectiveness
		etidronate and alendronate - cost effectiveness
BMD-MN Study
Body Mass Index
Bone densitometry
	bone mineral density
	bone density measurements
Breast cancer
	BMD as risk predictor
BUA. See Ultrasound Top
C
Caffeine intake
Calcitonin
	women with osteoporosis
	Salmon calcitonin
	calcitonin and etidronate
	fracture prevention
Calcitriol
	postmenopausal osteoporosis
	cardiac or lung transplantation
	idiopathic juvenile osteoporosis
Calcium
	intake
		calcium intake and bone mass
		dietary calcium intake
	supplementation
		calcium supplement
		rate of bone loss
		calcium and vitamin D supplementation
		systematic review
		calcium supplement
Calcium and vitamin D
	cost-effectiveness of supplementation
	intake
	supplementation
		vitamin D and calcium, and vitamin D
		vitamin D3 and calcium
		in corticosteroid treated patients
		corticosteroid induced osteporosis
		children with rheumatic disease
Canadian Multicentre Osteoporosis Study (CaMos)
	environmental risk factors
	bone densitometry
Cancer
	as cause of childhood osteoporosis
	risk, from estrogen replacement therapy
Carbonated drinks, effect of
Cardiovascular effects, of estrogen replacement therapy
	postmenopausal hormone therapy
	cardiovascular disease
Chartered Society of Physiotherapy guidelines
Children with osteoporosis
Climbing stairs,
Clodronate
Coeliac disease
	guidelines
Collaborative Group on Hormonal Factors in Breast Cancer
Congenital hip dysplasia, as risk factor for low BMD
Corticosteroid Induced Osteoporosis
Corticosteroid induced osteoporosis, guidelines
Corticosteroid use
	as cause of childhood osteoporosis
	as risk factor
Cost-effectiveness
	use of bone densitometry
	BUA
	bisophonate treatment
	hormone replacement therapy
	etidronate and alendronate
	calcium and vitamin D
CTX. See Serum C-telopeptide Top
D
Dairy foods
Danish Osteoporosis Prevention Study
	national cohort study
	foremarm fractures
Diet
	dietary calcium intake
	dairy foods
	defiency of protein
	food and nutrition
	vitamin d
	fruit and vegetable
	vitamin K
	salt
	diet and bone health
Dubbo Osteoporosis Study Top
E
Early Postmenopausal Intervention Cohort (EPIC) study
	thinness
	alendronate
Epidemiology, Risk Factors and Prevention
EPIDOS Study
	Osteoporosis Risk Assessment Instrument (ORAI)
	Serum C-telopeptide of type I collagen (CTX)
Estradiol, transdermal
Estrogen replacement therapy
	observational studies
	postmenopausal hormone therapy
	women with established osteoporosis
	posmenopausal osteoporosis
	Raloxifene
	prevention and treatment of osteoporosis in postmenopausal women
	bone loss
	human parathyroid hormone (PTH)
		flouride
	cancer risk
		epithelial ovarian cancer
		breast cancer
	cardiovascular effects
		established disease
	compared with raloxifene
	cost-effectiveness
Etidronate
	older women with established vertebral osteoporosis
	cyclical etidronate
	calcitonin and etidronate
	cyclic etidronate
	following renal tranplantation
	intermittent cyclic etidronate
		compared to alendronate
			alendronate and intermittent cyclical etidronate
			Bayesian analysis
European Foundation for Osteoporosis and Bone Disease (EFFO) guidelines
	guidelines for prevention and treatment
European Vertebral Osteoporosis Study (EVOS)
	vertebral deformity
	maternal history of hip fracture
Evidence type
Exercise training programmes
	postmenopausal women
	elderly adults
	ambulatory exercise
	osteoporosis in men - site-specific exercise Top
F
Female athlete triad
FICSIT trials
Fluoridated drinking water, effect of
Fluoride
	and calcium for male osteoporosis
	and estrogen replacement therapy
	and tibolone
Fozamax International Trial
FRACTURE Index
Fracture Intervention Trial (FIT)
	postmenopausal women
	treatment with alendronate
	preexisting vertebral fracture
	in older women
	phase III trials
Framington Osteoporosis Study
Fruit and vegetable intake Top
G
Genotypes, effect of
Growth hormone, for childhood osteoporosis
	idiopathic juvenile osteoporosis
	with juvenile chronic arthritis
Guidelines
	corticosteroid induced osteoporosis
	diet and bone health
	European Foundation for Osteoporosis
	for male osteoporosis
	management of coeliac and inflammatory bowel disease
	National Osteoporosis Foundation
	physiotherapy
	Royal College of Physicians
		authors recognition
		agree with recommendations
		guidelines
		Risedronate (Actonel)
		World Health Organisation
H
Health gain notation
Hip Intervention Program Study
Hip protectors
Hormone replacement therapy. See Estrogen replacement therapy
HRT. See Estrogen replacement therapy Top
I
Idiopathic juvenile osteoporosis
	cause
	growth hormone
Inflammatory bowel disease, guidelines
J
Juvenile chronic arthritis
K
Kuopio Osteoporosis Study
M
Maternal history of hip fracture
Men, osteoporosis in
	effect of physical activity
	effect of smoking
	physical activity
Menarch, effect of
Methodology
Milk intake. See Dairy food
Mineral intake
Multiple Outcomes of Raloxifene Evaluation (MORE) Trial
	women with low BMD
	postmenopausal women
N
National Osteoporosis Foundation (NOF) guidelines Top
O
Oral contraceptives, effect on BMD
Organ transplantation, and osteoporosis
Osteogenesis imperfecta
	in children
	growth hormone
Osteoporosis Research Advisory Group (ORAG)
Osteoporosis Risk Assessment Instrument
Osteoporosis Treatment Study Group
Osteoporotic Fractures Research Group
P
Pamidronate
	bone loss following renal transplantation
	lung transplantation
	intravenous pamidronare
	children with severe osteogenesis imperfecta
Parathyroid hormone
	postmenopausal osteoporosis
	human parathyroid hormone (PTH)
	pilot study
Parathyroid hormone and alendronate
Physical activity
	and dietary calcium intake
	high-impact physical activity
	exercise programmes in premenopausal women
	exercise programmes in postmenopausal women
	ambulatory exercise programme
	site-specific exercise
Physiotherapy guidelines
Prevalence of osteoporosis
Prevent Recurrence of Osteoporotic Fractures (PROOF) Study
Preventive factors
Primary and Secondary Prevention of Osteoporosis in Men
Primary Care Rheumatology Society guidelines
Primary Prevention of Bone Mineral Loss and Osteoporosis in Women
Protein intake
Protocol for Investment in Health Gain Top
Q
QUS. See Ultrasound
R
Raloxifene
	in early postmenopausal women
	treatment in postmenopausal women
	preserves BMD
	treatment with alendronate or raloxifene
	conjugated equine estrogens
	Raloxifene and cancer risk
	Raloxifene and cardiovascular risk
	Raloxifene and risk of venous thromboembolic disease
	Raloxifene compared with estrogen replacement therapy
Raloxifene Use for the Heart (RUTH) study
Risendronate
	for severe postmenopausal osteoporosis
	bone loss in postmenopausal women
	cost effetive
	corticosteroid-induced osteoporosis
Risk and preventive factors
Risk assessment instruments
Royal College of Physicians guidelines
	authors recognition
	agree with recommendations
	RCP, EFFO and NOF guidelines
	HRT
	Risedronate (Actonel)
	guidelines for prevention and treatment
	intermittent cyclic etidronate therapy Top
S
Salt intake
Screening and Diagnosis
Secondary Prevention and Treatment of Low Bone Density and Osteoporosis in Postmenopausal Women
Serum C-telopeptide
Smoking
	risk factorstudy
	BMD and BMI
	HRT
SOS. See Ultrasound
Soy isoflavones
Statins, effect on fracture risk
SSteroids. See corticosteroids
Study of Osteoporotic Fractures (SOF)
	likelihood to suffer
	FRACTURE Index
	estrogen replacement Top
T
Testosterone
	testosterone therapy
Thiazides
Thinness
	risk factors
	risk factor for low bone mass
	and smoking
	HRT
Tibolone
	and fluoride
Transplantation. See organ transplantation
Type of evidence
U
Ultrasound
	quantitative ultrasound (QUS)
	ultrasound measurements
	linear regression coefficients
	ultrasound devices
	cost effectivesness
	osteoporosis in children
V
Vertebral deformity
Vertebral Efficacy with Risedronate Therapy (VERT) Study
Vitamin D
	intake
	Vitamin D supplementation
		and calcium
		HRT
		and fractures
		and calcium supplementation
		community fracture prevention programmes
Vitamin K intake
W
Weight. See Thinness
World Health Organisation (WHO) guidelines
World Health Organisation assessment criteria
	for classification/diagnosis of osteoporosis
	for the primary prevention of bone mineral loss
	for the secondary prevention and treatment of low bone density
	primary and secondary prevention of osteoporosis in men

OSTEOPOROSIS